Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HIVACAR

Financiado

Evaluating a Combination of Immune based Therapies to Achieve a Functional Cure...

Evaluating a Combination of Immune based Therapies to Achieve a Functional Cure of HIV Infection The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4+ T-... ver más

30/06/2022

FUNDACIO CLINIC PE...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 650K€

Ver 21 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-06-30

SC1-PM-09-2016: New therapies for chronic diseases

I+D

Cerrada hace 8 años

0% 98% 100%

21 Participantes

FUNDACIO CLINIC PER A LA REC...

2.96M€ | Lider

TECNOLOGIA DE LA EXTRUSION D...

271.38K€ | Participante

HOSPITAL CLINIC DE BARCELONA

71.82K€ | Participante

ASPHALION

175.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2019-110275RB-I00 NUEVAS ESTRATEGIAS TERAPEUTICAS BASADAS EN INHIBIDORES DE TI... 157K€ Cerrado

RTI2018-097485-A-I00 NUEVAS ESTRATEGIAS BASADAS EN DC PARA POTENCIAR LA IMMUNOTER... 145K€ Cerrado

RTC-2017-6473-1 DESARROLLO DE UNA NUEVA VACUNA TERAPÉUTICA CONTRA EL VIH (NU... 1K€ Cerrado

EIN2019-102941 BUSQUEDA DE INMUNOGENOS VACUNALES DE LA ENVUELTA DEL VIH-1 O... 10K€ Cerrado

SAF2015-67334-R DESARROLLO DE UNA NUEVA ESTRATEGIA TERAPEUTICA INMUNE-ESPECI... 182K€ Cerrado

PID2021-127899OB-I00 RECEPTORES MODULADORES DEL ESTADO INMUNOMETABOLICO DE CELULA... 356K€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2016-12-12
Fecha Fin: 2022-06-30

Líder del proyecto

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 650K€

Presupuesto del proyecto 7M€

Descripción del proyecto The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4+ T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual costs related to HIV treatment and management and of the social public health as well as an improvement in the patients’ quality of life. HIVACAR project has been conceived under the framework of responsible research and innovation, so patients and other stakeholders will have a key role from the inception of the project until obtaining the results. Patients will be perfectly aware of how this therapy has been conceived and the real impact and change in their actual quality of life, as well as how the clinical trial has been designed and the consequences of participating in it. In addition, patients (and the general population) will tailor the project and its results dissemination and communication. This patient engagement will not be limited to the clinical trial but also to the rest of the activities of the project, so patients and the general society will be aware of how the research is developed and can include the patients’ point of view in the research activities. In addition, the socio-economic and psycho-social impact of the new treatment will be also analysed so overwhelming data on the benefits and impact of the new treatment will be obtained and shown to all the stakeholders.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores